Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment.
Malara N, Trunzo V, Foresta U, Amodio N, De Vitis S, Roveda L, Fava M, Coluccio M, Macrì R, Di Vito A, Costa N, Mignogna C, Britti D, Palma E, Mollace V. Malara N, et al. Among authors: amodio n. J Transl Med. 2016 May 12;14(1):133. doi: 10.1186/s12967-016-0876-y. J Transl Med. 2016. PMID: 27176720 Free PMC article.
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents.
Becherini P, Soncini D, Ravera S, Gelli E, Martinuzzi C, Giorgetti G, Cagnetta A, Guolo F, Ivaldi F, Miglino M, Aquino S, Todoerti K, Neri A, Benzi A, Passalacqua M, Nencioni A, Perrotta I, Gallo Cantafio ME, Amodio N, De Flora A, Bruzzone S, Lemoli RM, Cea M. Becherini P, et al. Among authors: amodio n. Antioxidants (Basel). 2023 Feb 15;12(2):494. doi: 10.3390/antiox12020494. Antioxidants (Basel). 2023. PMID: 36830052 Free PMC article.
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Blotta S, et al. Among authors: amodio n. Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20. Blood. 2012. PMID: 22821765 Free PMC article.
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: amodio n. Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3. Clin Cancer Res. 2012. PMID: 23035210 Free PMC article.
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Amodio N, et al. Cell Death Dis. 2012 Nov 29;3(11):e436. doi: 10.1038/cddis.2012.175. Cell Death Dis. 2012. PMID: 23190608 Free PMC article.
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Leone E, et al. Among authors: amodio n. Clin Cancer Res. 2013 Apr 15;19(8):2096-106. doi: 10.1158/1078-0432.CCR-12-3325. Epub 2013 Feb 27. Clin Cancer Res. 2013. PMID: 23446999 Free PMC article.
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: amodio n. Oncotarget. 2013 Feb;4(2):242-55. doi: 10.18632/oncotarget.820. Oncotarget. 2013. PMID: 23479461 Free PMC article.
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients.
Malara NM, Givigliano F, Trunzo V, Macrina L, Raso C, Amodio N, Aprigliano S, Minniti AM, Russo V, Roveda L, Coluccio ML, Fini M, Voci P, Prati U, Di Fabrizio E, Mollace V. Malara NM, et al. Among authors: amodio n. J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):717-31. J Biol Regul Homeost Agents. 2014. PMID: 25620181
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Pitari MR, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Morelli E, et al. Among authors: amodio n. Leukemia. 2015 Nov;29(11):2173-83. doi: 10.1038/leu.2015.124. Epub 2015 May 19. Leukemia. 2015. PMID: 25987254 Free PMC article.
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Gullà A, et al. Among authors: amodio n. Clin Cancer Res. 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2. Clin Cancer Res. 2016. PMID: 26527748 Free PMC article.
116 results